5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Azacitidine will be given at a dose of 75 mg/sqm (s.c) daily for 5 consecutive days every 28
days (every month) for a total of 8 courses to low risk MDSs according to IPSS scoring
system. In fact, several studies produced high rates of trilineage responses, reduces the
risk of progression to acute myeloid leukemia (AML) in high-risk MDS and improves the quality
of life (QoL). The use of 5-Aza in the earlier phases of MDS could reduce the proliferative
advantage of MDS clone and favour the regrowth of normal hematopoiesis.
Phase:
Phase 2
Details
Lead Sponsor:
Università degli Studi di Brescia
Collaborators:
Cremona Mantova University of Bologna University of Genova University of Siena University of Udine